Haleon Backs Guidance Despite Revenue, Profit Miss
Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts. Continue reading View comments
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
9.05 | |
8.95 | |
- | |
9.05 | |
8.8 | |
6.8133-9.5 | |
42 794 M | |
24.7222 | |
4 617 M | |
9 866 M | |
0 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts. Continue reading View comments
Key Insights Significantly high institutional ownership implies Haleon's stock price is sensitive to their trading actions The top 13 shareholders own 51% of the company Using data from analyst forec...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: